MITF-M dimer binds the BCL2A1 gene

Stable Identifier
R-HSA-9858559
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
BCL2A1 is a anti-apoptotic member of the BCL2 family that is specifically upregulated in melanomas compared to other examined cancer types, and is genomically amplified in 30% of melanomas (Haq et al, 2013). BCL2A1 is expressed at high levels in melanoma cell lines and at a lower level in melanocytes, and is essential for survival in MITF- and BCL2A1-amplified lines (Haq et al, 2013). Expression of BCL2A1 is driven in part by the binding of MITF-M to an E-box element in the promoter as assessed by ChIP and reporter gene assay, and mutation of the E-box abrogates MITF-dependent expression (Strub et al, 2011; Haq et al, 2013). Suppression of BCL2A1 expression in melanoma cell lines inhibits cell growth and reduces the tumorigenicity in mouse xenografts (Haq et al, 2013; reviewed Hartman and Czyz, 2015).
Literature References
PubMed ID Title Journal Year
21258399 Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma

Ye, T, Cormont, M, Keime, C, Kobi, D, Davidson, I, Le Gras, S, Giuliano, S, Bonet, C, Bertolotto, C, Ballotti, R, Strub, T

Oncogene 2011
25142731 Pro-survival role of MITF in melanoma

Hartman, ML, Czyz, M

J Invest Dermatol 2015
23447565 BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Song, JS, Yokoyama, S, Fisher, DE, Langer, R, Garraway, LA, Wargo, JA, Duncan, LM, Hoon, DS, Anderson, DG, Porter, D, Tran, TN, Love, KT, Haq, R, Morton, DL, Frederick, DT, Jönsson, GB, Hawryluk, EB, McHenry, K

Proc Natl Acad Sci U S A 2013
Participants
Participates
Authored
Reviewed
Created
Cite Us!